Company intelligence / Profile preview

Phlox Pharmaceuticals

Amsterdam, North Holland, Netherlands

Ownership: Private
Development stage: Other

Overview

Phlox Pharmaceuticals is a Dutch biotechnology company focused on developing precision medicines for rare genetic heart diseases. The company leverages a proprietary RNA-based platform to design antisense oligonucleotides (ASOs) that target the underlying genetic causes of laminopathies, specifically dilated cardiomyopathy (DCM) caused by LMNA mutations. Founded as a spin-off from the Amsterdam UMC and the Hubrecht Institute, Phlox aims to provide disease-modifying treatments for patients with high unmet medical needs. Its lead programs are currently in the pre-clinical stage, supported by leading European life science investors.

Therapeutic areas: CardiovascularRare Diseases
Modalities: Antisense oligonucleotideRNA therapy
Industry: Biotech

Partnerships

Amsterdam UMCHubrecht Institute

Beyond the preview

Go deeper on Phlox Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phlox Pharmaceuticals.

Explore the full profile